Champions Oncology, Inc. (CSBR)

NASDAQ: CSBR · IEX Real-Time Price · USD
8.99
+0.27 (3.10%)
Aug 8, 2022 4:30 PM EDT - Market closed
3.10%
Market Cap 121.57M
Revenue (ttm) 49.11M
Net Income (ttm) 548,000
Shares Out 13.52M
EPS (ttm) 0.04
PE Ratio 224.75
Forward PE 43.67
Dividend n/a
Ex-Dividend Date n/a
Volume 11,727
Open 8.73
Previous Close 8.72
Day's Range 8.68 - 9.41
52-Week Range 6.81 - 11.00
Beta 0.91
Analysts Buy
Price Target 14.96 (+66.4%)
Earnings Date Sep 12, 2022

About CSBR

Champions Oncology, Inc. develops and sells technology solutions and products to personalize the development and use of oncology drugs in the United States. Its Tumorgraft Technology Platform is an approach to personalizing cancer care based upon the implantation of human tumors in immune-deficient mice. The company, through its Tumorgraft Technology Platform, provides personalized cancer care based upon the implantation of human tumors in immune-deficient mice. It also offers Translational Oncology Solutions that utilizes its technology platfo... [Read more...]

Industry Life Sciences Tools & Services
IPO Date Mar 25, 1986
Employees 230
Stock Exchange NASDAQ
Ticker Symbol CSBR
Full Company Profile

Financial Performance

In 2022, CSBR's revenue was $49.11 million, an increase of 19.66% compared to the previous year's $41.04 million. Earnings were $548,000, an increase of 51.38%.

Financial Statements

Analyst Forecast

According to 9 analysts, the average rating for CSBR stock is "Buy." The 12-month stock price forecast is 14.96, which is an increase of 66.41% from the latest price.

Price Target
$14.96
(66.41% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Champions Oncology Reports Quarterly Revenue of $12.9 Million

Record Annual Revenue of $49.1 Million HACKENSACK, NJ / ACCESSWIRE / July 21, 2022 / Champions Oncology, Inc. (NASDAQ:CSBR), a leading global technology-enabled biotech that is transforming drug discove...

Champions Oncology to Announce Fourth Quarter Financial Results on Thursday, July 21, 2022

HACKENSACK, NJ / ACCESSWIRE / July 14, 2022 / Champions Oncology, Inc. (CSBR), a leading global technology-enabled biotech that is transforming drug discovery through innovative AI-driven pharmaco-pheno...

Champions Oncology Announces a Partnership with Cyclica to Develop Small Molecule Therapeutics

HACKENSACK, NJ and TORONTO, ON / ACCESSWIRE / May 31, 2022 / Champions Oncology, Inc. (NASDAQ:CSBR), a leading global technology-enabled biotech that is transforming drug discovery through innovative AI...

Champions Oncology Announces its Lumin Bioinformatics Platform Selected as a Finalist for the 'Best in Show' Competit...

HACKENSACK, NJ / ACCESSWIRE / May 3, 2022 / Champions Oncology, Inc. (NASDAQ:CSBR), a leading global technology-enabled biotech that is transforming drug discovery through innovative AI-driven pharmaco-...

Has Champions Oncology, Inc. (CSBR) Outpaced Other Medical Stocks This Year?

Here is how Champions Oncology, Inc. (CSBR) and Gamida Cell (GMDA) have performed compared to their sector so far this year.

Champions Oncology Reports Record Quarterly Revenue of $13.2 Million Reported Adjusted EBITDA of $1.5 million

HACKENSACK, NJ / ACCESSWIRE / March 15, 2022 / Champions Oncology, Inc. (Nasdaq:CSBR), a leading global technology-enabled biotech that is transforming drug discovery through innovative AI-driven pharma...

Champions Oncology to Announce Third Quarter Financial Results on Tuesday, March 15, 2022

HACKENSACK, NJ / ACCESSWIRE / March 11, 2022 / Champions Oncology, Inc. (CSBR), a leading global technology-enabled biotech that is transforming drug discovery through innovative AI-driven pharmaco-phen...

Champions Oncology Announces a Partnership with GigaMune to Discover Novel Tumor-Reactive T Cell Receptors

HACKENSACK, NJ / ACCESSWIRE / February 15, 2022 / Champions Oncology, Inc. (NASDAQ:CSBR), a leading global technology-enabled biotech that is transforming drug discovery through innovative AI-driven pha...

Champions Oncology Announces a Partnership with Fannin Innovation to Jointly Develop Therapeutic Raptamer Drug Conjug...

HACKENSACK, NJ / ACCESSWIRE / January 20, 2022 / Champions Oncology, Inc. (NASDAQ:CSBR), a leading global technology-enabled biotech that is transforming drug discovery through innovative AI-driven phar...

Champions Oncology Announces a Partnership with Alloy Therapeutics to Develop Therapeutic Monoclonal Antibodies for U...

HACKENSACK, NJ / ACCESSWIRE / January 4, 2022 / Champions Oncology, Inc. (Nasdaq:CSBR), a leading global technology-enabled biotech that is transforming drug discovery through innovative pharmacology, b...

Champions Oncology Reports Record Quarterly Revenue of $11.8 Million

Reported income from operations of $263,000 HACKENSACK, NJ / ACCESSWIRE / December 13, 2021 / Champions Oncology, Inc. (NASDAQ:CSBR), a leading global technology-enabled biotech that is transforming dru...

Champions Oncology to Announce Second Quarter Financial Results on Monday, December 13, 2021

HACKENSACK, NJ / ACCESSWIRE / December 6, 2021 / Champions Oncology, Inc. (NASDAQ:CSBR), leaders in transformative technology solutions utilized in oncology drug discovery and development will report it...

Champions Oncology Expands Global Biomarker Capabilities with Opening of European Laboratory at OpenZone Life Science...

HACKENSACK, NJ / ACCESSWIRE / October 20, 2021 / Champions Oncology (NASDAQ:CSBR), a technology-enabled research organization announced the opening of a European laboratory located in the renowned OpenZ...

Champions Oncology, Inc. (CSBR) Reports Q1 Loss, Tops Revenue Estimates

Champions Oncology, Inc. (CSBR) delivered earnings and revenue surprises of -200.00% and 2.30%, respectively, for the quarter ended July 2021. Do the numbers hold clues to what lies ahead for the stock?

Champions Oncology Reports Record Quarterly Revenue of $11.3 Million

HACKENSACK, NJ / ACCESSWIRE / September 13, 2021 / Champions Oncology, Inc. (Nasdaq:CSBR), leaders in transformative technology solutions utilized in drug discovery and development, today announced its ...

Champions Oncology, Inc. (CSBR) Reports Next Week: What You Should Expect

Champions Oncology, Inc. (CSBR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Champions Oncology to Announce First Quarter Financial Results on Monday, September 13, 2021

HACKENSACK, NJ / ACCESSWIRE / September 2, 2021 / Champions Oncology, Inc. (CSBR), leaders in transformative technology solutionsutilized in oncology drug discovery and development will report its finan...

Champions Oncology Announces an Expanded Corporate Strategy to Include Drug Discovery and Development

HACKENSACK, NJ / ACCESSWIRE / July 26, 2021 / Champions Oncology, Inc. (NASDAQ:CSBR), a leading global oncology technology solutions provider that is transforming drug discovery through innovative pharm...

Champions Oncology Reports Quarterly Revenue of $10.6 Million

Record Annual Revenue of $41 Million HACKENSACK, NJ / ACCESSWIRE / July 22, 2021 / Champions Oncology, Inc. (NASDAQ:CSBR), engaged in creating transformative technology solutions to be utilized in drug ...

Champions Oncology to Announce Fourth Quarter Financial Results on Thursday, July 22, 2021

HACKENSACK, NJ / ACCESSWIRE / July 14, 2021 / Champions Oncology, Inc. (NASDAQ:CSBR), a leading global oncology technology solutions provider engaged in transforming drug discovery through innovative ph...

Champions Oncology and BGI Americas Announce a Strategic Partnership to Provide Mass Spectrometry Proteomics, Metabol...

HACKENSACK, NJ / ACCESSWIRE / June 15, 2021 / Champions Oncology (NASDAQ:CSBR), a technology-enabled research organization announced today that they have entered into a strategic partnership with BGI Am...

Champions Oncology, Inc. (CSBR) Upgraded to Buy: What Does It Mean for the Stock?

Champions Oncology, Inc. (CSBR) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

7 Micro-Cap Stocks to Buy That Are Shining Right Now

The markets keep going up as new stimulus spending and the massive new infrastructure bill hit. These micro-cap stocks are bargains.

Strength Seen in Champions Oncology, Inc. (CSBR): Can Its 15.3% Jump Turn into More Strength?

Champions Oncology, Inc. (CSBR) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the...

Champions Oncology Reports Record Quarterly Revenue of $10.8 Million

HACKENSACK, NJ / ACCESSWIRE / March 11, 2021 / Champions Oncology, Inc. (NASDAQ:CSBR), a leading global oncology technology solutions provider engaged in transforming drug discovery and development thro...